Pharmaceutical Executive Daily: SanegeneBio's $1.5 Billion License Agreement with Genentech

Feb 03, 08:02 PM

Headliner
Share
Subscribe

In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application for a subcutaneous indication of Saphnelo, and SanegeneBio enters a $1 billion global licensing agreement with Genentech focused on RNAi development.

Share
Subscribe
Next
Pharmaceutical Executive Daily: Susan G. Komen Releases Breast Cancer Outlook for 2026
Top episodes
Healthcare Marketing Strategies for Reaching Diverse Audiences
by Pharmaceutical Executive
Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals
by Pharmaceutical Executive
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
by Pharmaceutical Executive